Please assess the completion status of the following clinical trial:

Trial Title: Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tuberculous meningitis, diagnosed based on clinical and/or CSF criteria~* Age 15 years old or more~* Hospitalized for the treatment~Exclusion Criteria:~* Pregnancy/lactation~* On TB treatment within 7 days before inclusion~* Elevated liver enzyme (\> 5x than normal values)~* Known hypersensitivity/intolerance to rifampicin or moxifloxacin~* Prolonged QTc interval in ECG or other detectable cardiac arrythmias, in the absence of hypokalemia~* Refusal to be included in the study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose rifampisin (Type: ACTIVE_COMPARATOR): Subjects in this arm receive 450 mg rifampicin orally.~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
- High dose rifampisin (Type: EXPERIMENTAL): Subjects in this arm receive 600 mg Rifampisin i.v. for 14 days, and the dosage will be switched to 450 mg Rifampisin p.o afterwards until completion of TB medication (in accordance with National TB Program)~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)

Based on this trial design, predict the completion outcome and termination type (if applicable).